Introduction from CEO Frank Reynolds
TEDxBigApple – Robert Langer
Biomaterials for the 21st Century
TEDxBoston – Frank Reynolds
Changing the Face of Neuroscience
“We’re Engineers…we’re working to solve challenging problems.” – Robert S. Langer
Over the last 40 years, PixarBio’s co-founders Frank Reynolds MSE/MBA and Dr. Robert S. Langer, David H. Koch Institute Professor at MIT, have made key contributions to the field of neuroscience through the invention of new biomaterials for the localized delivery of drugs over extended periods of time and for the delivery and support of sustaining cell growth.
One example is the Gliadel Wafer. Approved by the FDA in September 1996 and co-invented by Robert S. Langer, ScD, and Henry Brem, M.D., Chief of Neurosurgery at Johns Hopkins University who had worked with Langer in the lab of renowned cancer researcher Judah Folkman, M.D., this dime-sized wafer was able to deliver chemotherapy directly to a site in the brain where a tumor had been removed. The Gliadel Wafer became the first therapy in more than two decades to extend the lives of patients with a deadly brain cancer called glioblastoma. (1) NIH http://www.nih.gov/about/people/langer.htm
In 2006, Frank Reynolds and Dr. Langer co-founded InVivo Therapeutics Corporation to advance biomaterials for spinal cord injury (SCI) to human studies. The objective was to advance biomaterial scaffold devices from rodents, through primates and into human studies for acute spinal cord injuries. The US FDA approved those human studies in 2013 with patient enrollment expected to begin in early 2014.
We know that sustained levels of dopamine is the objective of Parkinson’s disease interventions. PixarBio Corporation will invent novel smart materials and develop a new platform to achieve sustained release of dopamine beyond one year. We expect that the new smart materials will have numerous neurological applications beyond Parkinson’s disease.
We believe that over the next 5 years, we will create the opportunity to build a new clinical franchise in medicine and lead the next phase of the biomaterials industry’s growth as industry learning curves condense and time to market shortens.
PixarBio considers the biomaterials space as an undervalued sector and ripe for consolidation. Our team will apply our expertise to identify underperforming assets and explore M&A to lead consolidation of the biomaterials industry’s undervalued assets.
Historically, R&D models around biomaterials often fall into smaller segments of larger R&D budgets and therefore they do not receive the proper product development support to succeed. PixarBio will utilize our time-tested and proven ROI-driven R&D model by embedding strategic vision down to the bench.
PixarBio will spend its first year exploring M&A while revisiting some of neuroscience’s most complicated challenges as we develop our treatments for sustained release of dopamine or dopamine triggers patenting new biomaterials, processes, procedures for all aspects of R&D and commercialization of the critically needed smart biomaterials.
Neuroscience will remain the most unknown frontier in science and medicine where the opportunity for biomaterial interventions seems endless.